BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 28483374)

  • 1.
    Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
    Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD
    Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Update on the use of FDG-PET/CT in malignant lymphoma].
    Terauchi T
    Rinsho Ketsueki; 2016; 57(10):2008-2012. PubMed ID: 27795508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
    McCarten KM; Nadel HR; Shulkin BL; Cho SY
    Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
    Sioka C
    Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAC y PET/TC con 18-FDG para evaluar la respuesta al tratamiento en linfoma de Hodgkin y no Hodgkin.
    Vargas-Partida T; Hernández-Cruz M; Ruiz-Eng R; Montiel-Jarquín ÁJ; Vázquez-Cruz E; López-Colombo A
    Gac Med Mex; 2019; 155(4):386-390. PubMed ID: 31486785
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Dercle L; Seban RD; Lazarovici J; Schwartz LH; Houot R; Ammari S; Danu A; Edeline V; Marabelle A; Ribrag V; Michot JM
    J Nucl Med; 2018 Jan; 59(1):15-24. PubMed ID: 28596157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
    Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
    Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET/CT in lymphoma.
    Juweid ME
    Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/CT: Clinical role in lymphomas.
    Papathanasiou N
    Hell J Nucl Med; 2023; 26 Suppl():36-37. PubMed ID: 37658560
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
    Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose PET/computerized tomography in identifying bone marrow infiltration in new patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Kandeel AA; Hussein M; Zidan L; Younis J; Edesa W; Alsayed Y
    Nucl Med Commun; 2020 Mar; 41(3):269-279. PubMed ID: 31895758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Role of Functional Imaging in the Management of Lymphoma.
    Cheson BD; Meignan M
    Curr Oncol Rep; 2021 Nov; 23(12):144. PubMed ID: 34735647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
    Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
    Juweid ME; Mueller M; Alhouri A; A-Risheq MZ; Mottaghy FM
    Cancer; 2021 Oct; 127(20):3727-3741. PubMed ID: 34286864
    [No Abstract]   [Full Text] [Related]  

  • 20. FDG-PET/CT in the management of lymphomas: current status and future directions.
    El-Galaly TC; Villa D; Gormsen LC; Baech J; Lo A; Cheah CY
    J Intern Med; 2018 Oct; 284(4):358-376. PubMed ID: 29989234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.